Reported Saturday, Sutro Highlights Late-Breaking Refrαme-O1 Data Demonstrating 32% ORR And 96% DCR With Optimized Luvelta Dosing In PROC Patients

Late-Breaking Oral Presentation Highlights:

• At the selected optimized dose (5.2 mg/kg), luvelta achieved an ORR of 32%1 and a disease control rate (DCR) of 96% compared to an ORR of 13.8% and a DCR of 69% for the 4.3 mg/kg group.
• The demonstrated clinical activity in the 5.2 mg/kg group was consistent in patients across all levels of FRα expression of 25% or greater, with an ORR of 30.8% and a DCR of 100% for positive staining (PS) 2+ ≥75% (eligible for approved FRα-targeting ADC) and an ORR of 33.3%1 and DCR of 91.7%1 for PS2+ < 75%.
• Safety was consistent across dosing groups, with no new safety signals observed and neutropenia well-managed.
• The majority of patients across both dose cohorts received prior bevacizumab.